The global market for Sexually Transmitted Diseases (STDs) Drug was valued at US$ 2450 million in the year 2024 and is projected to reach a revised size of US$ 3639 million by 2031, growing at a CAGR of 5.9% during the forecast period.

Sexually Transmitted Diseases (STDs) Drug Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Sexually Transmitted Diseases (STDs) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sexually Transmitted Diseases (STDs) Drug.

The Sexually Transmitted Diseases (STDs) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Sexually Transmitted Diseases (STDs) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Sexually Transmitted Diseases (STDs) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Sexually Transmitted Diseases (STDs) Drug Market Report

Report Metric	Details
Report Name	Sexually Transmitted Diseases (STDs) Drug Market
Accounted market size in year	US$ 2450 million
Forecasted market size in 2031	US$ 3639 million
CAGR	5.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Chlamydia Gonorrhea Syphilis Genital herpes HPV HIV / AIDS
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, AbbVie, Inc., Gilead Sciences, GlaxoSmithKline Plc, Merck & Co., Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Sexually Transmitted Diseases (STDs) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Sexually Transmitted Diseases (STDs) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Sexually Transmitted Diseases (STDs) Drug Market growing?

Ans: The Sexually Transmitted Diseases (STDs) Drug Market witnessing a CAGR of 5.9% during the forecast period 2025-2031.

What is the Sexually Transmitted Diseases (STDs) Drug Market size in 2031?

Ans: The Sexually Transmitted Diseases (STDs) Drug Market size in 2031 will be US$ 3639 million.

Who are the main players in the Sexually Transmitted Diseases (STDs) Drug Market report?

Ans: The main players in the Sexually Transmitted Diseases (STDs) Drug Market are Pfizer, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, AbbVie, Inc., Gilead Sciences, GlaxoSmithKline Plc, Merck & Co., Inc.

What are the Application segmentation covered in the Sexually Transmitted Diseases (STDs) Drug Market report?

Ans: The Applications covered in the Sexually Transmitted Diseases (STDs) Drug Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Sexually Transmitted Diseases (STDs) Drug Market report?

Ans: The Types covered in the Sexually Transmitted Diseases (STDs) Drug Market report are Chlamydia, Gonorrhea, Syphilis, Genital herpes, HPV, HIV / AIDS

1 Sexually Transmitted Diseases (STDs) Drug Market Overview

1.1 Product Definition

1.2 Sexually Transmitted Diseases (STDs) Drug by Type

1.2.1 Global Sexually Transmitted Diseases (STDs) Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 Chlamydia

1.2.3 Gonorrhea

1.2.4 Syphilis

1.2.5 Genital herpes

1.2.6 HPV

1.2.7 HIV / AIDS

1.3 Sexually Transmitted Diseases (STDs) Drug by Application

1.3.1 Global Sexually Transmitted Diseases (STDs) Drug Market Value by Application (2024 VS 2031)

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Global Sexually Transmitted Diseases (STDs) Drug Market Size Estimates and Forecasts

1.4.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue 2020-2031

1.4.2 Global Sexually Transmitted Diseases (STDs) Drug Sales 2020-2031

1.4.3 Global Sexually Transmitted Diseases (STDs) Drug Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Sexually Transmitted Diseases (STDs) Drug Market Competition by Manufacturers

2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Sexually Transmitted Diseases (STDs) Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Sexually Transmitted Diseases (STDs) Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Product Type & Application

2.7 Global Key Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Date of Enter into This Industry

2.8 Global Sexually Transmitted Diseases (STDs) Drug Market Competitive Situation and Trends

2.8.1 Global Sexually Transmitted Diseases (STDs) Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Sexually Transmitted Diseases (STDs) Drug Players Market Share by Revenue

2.8.3 Global Sexually Transmitted Diseases (STDs) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Sexually Transmitted Diseases (STDs) Drug Market Scenario by Region

3.1 Global Sexually Transmitted Diseases (STDs) Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2020-2031

3.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2020-2025

3.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2026-2031

3.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2020-2031

3.3.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2020-2025

3.3.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2026-2031

3.4 North America Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country

3.4.1 North America Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2031)

3.4.3 North America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country

3.5.1 Europe Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2031)

3.5.3 Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country

3.7.1 Latin America Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2031)

3.7.3 Latin America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2020-2031)

4.1.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2020-2025)

4.1.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2026-2031)

4.1.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2020-2031)

4.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2020-2031)

4.2.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2020-2025)

4.2.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2026-2031)

4.2.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2020-2031)

4.3 Global Sexually Transmitted Diseases (STDs) Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2020-2031)

5.1.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2020-2025)

5.1.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2026-2031)

5.1.3 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2020-2031)

5.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2020-2031)

5.2.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2020-2025)

5.2.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2026-2031)

5.2.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2020-2031)

5.3 Global Sexually Transmitted Diseases (STDs) Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Company Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 Hoffmann La Roche

6.2.1 Hoffmann La Roche Company Information

6.2.2 Hoffmann La Roche Description and Business Overview

6.2.3 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.2.5 Hoffmann La Roche Recent Developments/Updates

6.3 Bayer Healthcare

6.3.1 Bayer Healthcare Company Information

6.3.2 Bayer Healthcare Description and Business Overview

6.3.3 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.3.5 Bayer Healthcare Recent Developments/Updates

6.4 Eli Lilly

6.4.1 Eli Lilly Company Information

6.4.2 Eli Lilly Description and Business Overview

6.4.3 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.4.5 Eli Lilly Recent Developments/Updates

6.5 Johnson & Johnson

6.5.1 Johnson & Johnson Company Information

6.5.2 Johnson & Johnson Description and Business Overview

6.5.3 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.5.5 Johnson & Johnson Recent Developments/Updates

6.6 Bristol-Myers Squibb

6.6.1 Bristol-Myers Squibb Company Information

6.6.2 Bristol-Myers Squibb Description and Business Overview

6.6.3 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.6.5 Bristol-Myers Squibb Recent Developments/Updates

6.7 AbbVie, Inc.

6.7.1 AbbVie, Inc. Company Information

6.7.2 AbbVie, Inc. Description and Business Overview

6.7.3 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.7.5 AbbVie, Inc. Recent Developments/Updates

6.8 Gilead Sciences

6.8.1 Gilead Sciences Company Information

6.8.2 Gilead Sciences Description and Business Overview

6.8.3 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.8.5 Gilead Sciences Recent Developments/Updates

6.9 GlaxoSmithKline Plc

6.9.1 GlaxoSmithKline Plc Company Information

6.9.2 GlaxoSmithKline Plc Description and Business Overview

6.9.3 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.9.5 GlaxoSmithKline Plc Recent Developments/Updates

6.10 Merck & Co., Inc.

6.10.1 Merck & Co., Inc. Company Information

6.10.2 Merck & Co., Inc. Description and Business Overview

6.10.3 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio

6.10.5 Merck & Co., Inc. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Sexually Transmitted Diseases (STDs) Drug Industry Chain Analysis

7.2 Sexually Transmitted Diseases (STDs) Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Sexually Transmitted Diseases (STDs) Drug Production Mode & Process Analysis

7.4 Sexually Transmitted Diseases (STDs) Drug Sales and Marketing

7.4.1 Sexually Transmitted Diseases (STDs) Drug Sales Channels

7.4.2 Sexually Transmitted Diseases (STDs) Drug Distributors

7.5 Sexually Transmitted Diseases (STDs) Drug Customer Analysis

8 Sexually Transmitted Diseases (STDs) Drug Market Dynamics

8.1 Sexually Transmitted Diseases (STDs) Drug Industry Trends

8.2 Sexually Transmitted Diseases (STDs) Drug Market Drivers

8.3 Sexually Transmitted Diseases (STDs) Drug Market Challenges

8.4 Sexually Transmitted Diseases (STDs) Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Sexually Transmitted Diseases (STDs) Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Sexually Transmitted Diseases (STDs) Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Sexually Transmitted Diseases (STDs) Drug Market Competitive Situation by Manufacturers in 2024

Table 4. Global Sexually Transmitted Diseases (STDs) Drug Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Sexually Transmitted Diseases (STDs) Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Sexually Transmitted Diseases (STDs) Drug Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Sexually Transmitted Diseases (STDs) Drug Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Sexually Transmitted Diseases (STDs) Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Product Type & Application

Table 12. Global Key Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Sexually Transmitted Diseases (STDs) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sexually Transmitted Diseases (STDs) Drug as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Sexually Transmitted Diseases (STDs) Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2020-2025) & (K Units)

Table 18. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2020-2025)

Table 19. Global Sexually Transmitted Diseases (STDs) Drug Sales by Region (2026-2031) & (K Units)

Table 20. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2026-2031)

Table 21. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2020-2025)

Table 23. Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2026-2031)

Table 25. North America Sexually Transmitted Diseases (STDs) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2025) & (K Units)

Table 27. North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2026-2031) & (K Units)

Table 28. North America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2025) & (K Units)

Table 32. Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2026-2031) & (K Units)

Table 33. Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Sexually Transmitted Diseases (STDs) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Sexually Transmitted Diseases (STDs) Drug Sales (K Units) by Type (2020-2025)

Table 51. Global Sexually Transmitted Diseases (STDs) Drug Sales (K Units) by Type (2026-2031)

Table 52. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2020-2025)

Table 53. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2026-2031)

Table 54. Global Sexually Transmitted Diseases (STDs) Drug Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Sexually Transmitted Diseases (STDs) Drug Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2020-2025)

Table 57. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2026-2031)

Table 58. Global Sexually Transmitted Diseases (STDs) Drug Price (USD/Unit) by Type (2020-2025)

Table 59. Global Sexually Transmitted Diseases (STDs) Drug Price (USD/Unit) by Type (2026-2031)

Table 60. Global Sexually Transmitted Diseases (STDs) Drug Sales (K Units) by Application (2020-2025)

Table 61. Global Sexually Transmitted Diseases (STDs) Drug Sales (K Units) by Application (2026-2031)

Table 62. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2020-2025)

Table 63. Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2026-2031)

Table 64. Global Sexually Transmitted Diseases (STDs) Drug Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Sexually Transmitted Diseases (STDs) Drug Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2020-2025)

Table 67. Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2026-2031)

Table 68. Global Sexually Transmitted Diseases (STDs) Drug Price (USD/Unit) by Application (2020-2025)

Table 69. Global Sexually Transmitted Diseases (STDs) Drug Price (USD/Unit) by Application (2026-2031)

Table 70. Pfizer Company Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Pfizer Sexually Transmitted Diseases (STDs) Drug Product

Table 74. Pfizer Recent Developments/Updates

Table 75. Hoffmann La Roche Company Information

Table 76. Hoffmann La Roche Description and Business Overview

Table 77. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product

Table 79. Hoffmann La Roche Recent Developments/Updates

Table 80. Bayer Healthcare Company Information

Table 81. Bayer Healthcare Description and Business Overview

Table 82. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product

Table 84. Bayer Healthcare Recent Developments/Updates

Table 85. Eli Lilly Company Information

Table 86. Eli Lilly Description and Business Overview

Table 87. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product

Table 89. Eli Lilly Recent Developments/Updates

Table 90. Johnson & Johnson Company Information

Table 91. Johnson & Johnson Description and Business Overview

Table 92. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product

Table 94. Johnson & Johnson Recent Developments/Updates

Table 95. Bristol-Myers Squibb Company Information

Table 96. Bristol-Myers Squibb Description and Business Overview

Table 97. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product

Table 99. Bristol-Myers Squibb Recent Developments/Updates

Table 100. AbbVie, Inc. Company Information

Table 101. AbbVie, Inc. Description and Business Overview

Table 102. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product

Table 104. AbbVie, Inc. Recent Developments/Updates

Table 105. Gilead Sciences Company Information

Table 106. Gilead Sciences Description and Business Overview

Table 107. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product

Table 109. Gilead Sciences Recent Developments/Updates

Table 110. GlaxoSmithKline Plc Company Information

Table 111. GlaxoSmithKline Plc Description and Business Overview

Table 112. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product

Table 114. GlaxoSmithKline Plc Recent Developments/Updates

Table 115. Merck & Co., Inc. Company Information

Table 116. Merck & Co., Inc. Description and Business Overview

Table 117. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product

Table 119. Merck & Co., Inc. Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Sexually Transmitted Diseases (STDs) Drug Distributors List

Table 123. Sexually Transmitted Diseases (STDs) Drug Customers List

Table 124. Sexually Transmitted Diseases (STDs) Drug Market Trends

Table 125. Sexually Transmitted Diseases (STDs) Drug Market Drivers

Table 126. Sexually Transmitted Diseases (STDs) Drug Market Challenges

Table 127. Sexually Transmitted Diseases (STDs) Drug Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Sexually Transmitted Diseases (STDs) Drug

Figure 2. Global Sexually Transmitted Diseases (STDs) Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Sexually Transmitted Diseases (STDs) Drug Market Share by Type: 2024 & 2031

Figure 4. Chlamydia Product Picture

Figure 5. Gonorrhea Product Picture

Figure 6. Syphilis Product Picture

Figure 7. Genital herpes Product Picture

Figure 8. HPV Product Picture

Figure 9. HIV / AIDS Product Picture

Figure 10. Global Sexually Transmitted Diseases (STDs) Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 11. Global Sexually Transmitted Diseases (STDs) Drug Market Share by Application: 2024 & 2031

Figure 12. Hospital Pharmacies

Figure 13. Retail Pharmacies

Figure 14. Online Pharmacies

Figure 15. Global Sexually Transmitted Diseases (STDs) Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Sexually Transmitted Diseases (STDs) Drug Market Size (2020-2031) & (US$ Million)

Figure 17. Global Sexually Transmitted Diseases (STDs) Drug Sales (2020-2031) & (K Units)

Figure 18. Global Sexually Transmitted Diseases (STDs) Drug Average Price (USD/Unit) & (2020-2031)

Figure 19. Sexually Transmitted Diseases (STDs) Drug Report Years Considered

Figure 20. Sexually Transmitted Diseases (STDs) Drug Sales Share by Manufacturers in 2024

Figure 21. Global Sexually Transmitted Diseases (STDs) Drug Revenue Share by Manufacturers in 2024

Figure 22. Global 5 and 10 Largest Sexually Transmitted Diseases (STDs) Drug Players: Market Share by Revenue in Sexually Transmitted Diseases (STDs) Drug in 2024

Figure 23. Sexually Transmitted Diseases (STDs) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 24. Global Sexually Transmitted Diseases (STDs) Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 25. North America Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2020-2031)

Figure 26. North America Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Country (2020-2031)

Figure 27. U.S. Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Canada Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Europe Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2020-2031)

Figure 30. Europe Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Country (2020-2031)

Figure 31. Germany Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. France Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. U.K. Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Italy Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Russia Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Region (2020-2031)

Figure 37. Asia Pacific Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Region (2020-2031)

Figure 38. China Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Japan Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. South Korea Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. India Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Australia Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. China Taiwan Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Indonesia Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Thailand Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Malaysia Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Latin America Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2020-2031)

Figure 48. Latin America Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Country (2020-2031)

Figure 49. Mexico Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Brazil Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Argentina Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Country (2020-2031)

Figure 53. Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Country (2020-2031)

Figure 54. Turkey Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. UAE Sexually Transmitted Diseases (STDs) Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Global Sales Market Share of Sexually Transmitted Diseases (STDs) Drug by Type (2020-2031)

Figure 58. Global Revenue Market Share of Sexually Transmitted Diseases (STDs) Drug by Type (2020-2031)

Figure 59. Global Sexually Transmitted Diseases (STDs) Drug Price (USD/Unit) by Type (2020-2031)

Figure 60. Global Sales Market Share of Sexually Transmitted Diseases (STDs) Drug by Application (2020-2031)

Figure 61. Global Revenue Market Share of Sexually Transmitted Diseases (STDs) Drug by Application (2020-2031)

Figure 62. Global Sexually Transmitted Diseases (STDs) Drug Price (USD/Unit) by Application (2020-2031)

Figure 63. Sexually Transmitted Diseases (STDs) Drug Value Chain

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions